Körber Pharma Briefing Note
Axendia was recently briefed by Pierrick Lebigre, Vice President Product at Körber Pharma. For more than three decades, its PAS-X Manufacturing Execution System (MES) has been synonymous with large-scale pharmaceutical manufacturing. The platform’s success has been built on its ability to support complex global operations, stringent compliance requirements, and highly configurable manufacturing processes. However, a significant portion of the life sciences industry has remained underserved by traditional MES deployments.
With the introduction of PAS-X Neo, Körber Pharma is targeting a segment that has historically struggled to justify the cost, complexity, and implementation timelines associated with enterprise MES platforms: small and mid-sized pharmaceutical manufacturers, emerging biotechs, contract manufacturers, and smaller production sites within large pharmaceutical organizations.
MES Competing with Paper
According to Pierrick, the company recognized that the MES value proposition does not always align with the realities of smaller operations. “What we see is that nowadays, the return on investment is not always there, especially for the requirements of smaller sites….what we call typically either small and medium, or Tier 2, Tier 3 sites,” Lebigre explained. He noted that many organizations lack the resources “to embark on a large-scale digital transformation project.
This observation reflects a broader industry challenge. While digital manufacturing has become increasingly important for compliance, data integrity, and operational efficiency, many smaller manufacturers continue to rely on paper-based processes. In fact, he characterized the competitive landscape differently than most MES vendors. “What we realized is that for those small and medium pharma customers, our main competitor is really paper. Today, we see a strong push to leverage AI to bring efficiency gains, but paper-based manufacturing recording does not enable this.” said Lebigre.
Rather than introducing a scaled-down version of PAS-X MES, Körber Pharma has taken a different approach. PAS-X Neo is designed as a purpose-built product with its own architecture, workflows, and operating model. When asked whether PAS-X Neo was simply a lighter version of PAS-X MES, Lebigre was direct: “The answer is no. It really is a new product, a complete new one…it’s own product.”
This distinction is important because PAS-X Neo addresses a fundamentally different set of customer requirements. While PAS-X MES emphasizes flexibility and extensive configurability, PAS-X Neo focuses on standardization, speed, and simplicity.
The platform relies on predefined process templates and best-practice workflows designed to reduce implementation effort. Rather than requiring manufacturers to model highly customized electronic batch records from scratch, PAS-X Neo leverages standardized process building blocks informed by Körber’s decades of pharmaceutical manufacturing experience.
Accelerating Time to Value
The platform combines standardized workflows with AI-enabled migration capabilities that can help convert existing paper records and process documentation into digital manufacturing records. This approach allows manufacturers to begin their digital transformation journey without redesigning every process from the ground up.
“We want to offer predefined libraries and templates of process-oriented building blocks,” Lebigre explained. “We need to have some level of predefined templates here to ensure rapid adoption and implementation.”
The strategy is designed to achieve one of the platform’s most compelling value propositions: accelerated time-to-value. Traditional MES implementations often require six to eighteen months before reaching production use. PAS-X Neo aims to compress that timeline dramatically.
“We’re aiming for only a few weeks between the first sales contacts, the acquisition of the system, and the first use in production,” said Lebigre.
PAS-X Neo is being developed as a cloud-native Software-as-a-Service (SaaS) platform. For smaller manufacturers that may lack specialized IT resources, SaaS delivery eliminates much of the infrastructure burden traditionally associated with MES deployments.
“Most small and medium sized manufacturers don’t have the bandwidth and the skill sets to maintain a modern system nowadays,” Lebigre observed. “That’s why this product is going to be software as a service.”
Beyond addressing the needs of smaller standalone manufacturers, PAS-X Neo also serves a strategic role within Körber Pharma’s broader product portfolio. The company envisions scenarios where large pharmaceutical organizations may deploy PAS-X MES at major commercial sites while using PAS-X Neo at clinical, development, or smaller production facilities.
As organizations grow, Körber Pharma intends to support migration paths between the two platforms through interoperability capabilities and shared data models. “The two solutions are meant to be complementary, not necessarily competing with one another,” Lebigre said.
This interoperability strategy may prove particularly valuable for pharmaceutical companies seeking to standardize manufacturing execution across diverse site types, maintain appropriate levels of functionality and investment, and seeking solutions for flexible technology transfer opportunities between sites.
In Brief
The launch of PAS-X Neo signals a broader shift occurring across life sciences manufacturing. Digital transformation is no longer reserved for the industry’s largest facilities. As regulatory expectations continue to increase and operational efficiency becomes more critical, smaller manufacturers are facing many of the same pressures as their larger counterparts.
Körber Pharma’s bet is that the next phase of MES adoption will not be driven solely by feature richness or configurability, but by accessibility, speed, and practical deployment models. If PAS-X Neo delivers on its promise of rapid implementation, cloud-native operation, and pharmaceutical-grade compliance, it could significantly expand MES adoption among organizations that have historically remained on the sidelines of manufacturing modernization.
For an industry where paper remains the primary competitor, that opportunity may be larger than many realize.
We will continue to provide updates on Körber Pharma as they become available.
Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry
Stay Connected with Axendia!
Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.
- Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
- Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
- Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia
Let’s drive innovation together!
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.